Dyne Therapeutics, Inc.
DYN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,084 | $1,150 | $2,403 |
| - Cash | $574 | $485 | $472 | $435 |
| + Debt | $16 | $22 | $23 | $24 |
| Enterprise Value | – | $621 | $701 | $1,991 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$105 | -$110 | -$122 | -$97 |
| % Margin | – | – | – | – |
| Net Income | -$108 | -$111 | -$115 | -$90 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.76 | -0.97 | -1.05 | -0.88 |
| % Growth | 21.6% | 7.6% | -19.3% | – |
| Operating Cash Flow | -$91 | -$95 | -$106 | -$84 |
| Capital Expenditures | -$19 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$110 | -$95 | -$107 | -$85 |